With the clinical approval and widespread application of ALK inhibitors such as Crizotinib, Alectinib, and Ceritinib in the treatment of ALK-positive malignancies, these agents have demonstrated substantial efficacy in delaying tumor progression [13]. Here, ALK is linked to neoplasm.